Merck Sharp + Dohme Corp.

Microsoft Technology Licensing, LLC

Merck + Co., Inc.

Arena Pharmaceuticals, Inc.

Rui Liang

Emma R Parmee

Yusheng Xiong

Wonsuk Chang

Jared N Cumming

Michael D Altman

Jongwon Lim

Tony Siu

Benjamin Wesley Trotter

Hao Xu

Yue Li

Ryan D Otte

Andrew M Haidle

Namendra Kumar

James Patrick Jewell

Timothy J Henderson

Linda Brockunier

Abhilash Chandrasekharan Nair

Min Lu

Jian Guo

Xin He

Jason Eugene Imbriglio

Joel Harodi Marquez Catano

Kensaku Sueda

Gaurav Pancholi

Denis Postu

Balvinder Kaur Thind

Nagaswapna Bhamidipati

Rama Krishan Prasad Satya Prakash

Artur Pawel Kania

Jindrich Parus

Martin Petrla

James R Tata

Subharekha Raghavan

Matthew A Larsen

Sriram Tyagarajan

Brandon D Cash

Kevin Tyler Chapman

Shawn P Walsh

Darby Schmidt

Quang T Truong

Joseph Leslie Duffy

Srivatsa K Srinivasan

John E Stelmach

Somesh Chaturmohta

Hyewon Youm

Ranjith Narayanan

Zenon D Konteatis

Milica Jovanovic

Irena Atov

Milica Jovanović

Li Zhang

Amit Gupta

Hong Shen

Steven L Colletti

Jyh-Han Lin

Zhicai Wu

Alan B Northrup

Amritansh Raghav

Zhijian Lu

Fa-Xiang Ding

Songnian Lin

Ronald M Kim

Hong Liu

Derun Li

Brian M Andresen

Graeme Semple

Tawfik Gharbaoui

Yiu-Ming Leung

Matthew Lloyd Childers

Clare London

Xibin Liao

Tanweer A Khan

Jae-Kyu Jung

Jiang Chang

Scott B Hoyt

Angela Dawn Kerekes

Fengqi Zhang

Patrick E Plaisted

Pengcheng Patrick Shao

Cindy Kwan

Aravind Seshadri

Feng Ye

Libo Xu

Anand Muthurajan

Edward Metzger

Jerry Andrew Taylor

Thomas O Schrader

Kake Zhao

Claire Lankin

Yang Yu

Keith Rosauer

Ke-Cheng Huang

Qingmei Hong

Jonathan A Groeper

Sergei Osobov

Philip J Skinner

Kenneth Marby

Ming You

Christian P Stevenson

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject.

Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes

Failover functionality is by identifying at least two network paths for a media communications session between a virtual machine at a computing environment and a client application. Unique Internet Protocol (IP) addresses are assigned for the at least two network paths. Based on application and network metrics at the computing environment, a network condition at the computing environment is determined that is indicative of a performance degradation of the media communications session. A signal is communicated to the client service indicating a switch to a second path of the at least two network paths and a second of the unique IP addresses.

Convergence for time sensitive cloud applications

An online meeting system begins the process of connecting a user to an online meeting when a request is received from a user to start or join the online meeting. In response to the request, a pre-meeting user interface (UI) is displayed having a user interface control which, when activated, enables transmission of audio and/or video data for the online meeting, and prior to activation of the control, connection parameters are shared with an online meeting service to preheat the meeting. In response to activation of the control, transmission of audio and/or video data for the online meeting is enabled.

Reducing setup time for online meetings

An online meeting system begins the process of connecting a user to an online meeting when the user enters a prejoin dialog for choosing meeting settings, rather than waiting until the user chooses to actually join the meeting after entering settings. Starting the meeting connection process at this time allows a shorter perceived connection time to the meeting and thus reduces user frustration with the meeting system.

A method and apparatus is described for rendering web pages by a wireless device in order to reduce an amount of data transmitted over-the-air to the wireless device. In one embodiment, a method is performed by a server, comprising receiving a markup language document from a web server via a network interface, the markup language document corresponding to a web page. Next, the markup language document is parsed into a number of blocks by a processor, each of the blocks comprising code representing original content of the web page. Then, the processor creates one or more replacement blocks, each of the replacement blocks corresponding to a respective one of the blocks, each of the replacement blocks comprising code representing substituted content of the web page. Some of the blocks and at least one of the replacement blocks are then sent to a wireless device for rendering.

Web page rendering on wireless devices

The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, X, Y, R, R, R, Rand n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples. 

Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders

A class of polycyclic compounds of general formula (I), of general formula (I'), or of general formula (I&#x2033;), wherein Base, Base, Y, Y, X, X, X, X, X, X, X, X, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds. 

Cyclic di-nucleotide compounds as sting agonists

Compounds of general formula (Ia), compounds of general formula (Ia'), compounds of general formula (Ib), compounds of general formula (Ib&#x2032;), compounds of general formula (I), compounds of general formula (I&#x2032;), and their pharmaceutically acceptable salts, wherein R, R, R, R, R, R, R, R, X, X, and Xare defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.

Benzo[b]thiophene compounds as STING agonists

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 ('DGAT2') and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. 

Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2

Benzo[b]thiophene compounds as sting agonists

Growing community of inventors

East Brunswick, NJ, United States of America

Rui Liang